Cancer Family
Hematopoietic and Lymphoid Cell Neoplasm
CI-CAN-00000023Explore in graph →
HematologicNon-malignant4,231 active trials98 approved drugs1,009 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000023Explore in graph →
Clinical trials
18,680 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01724294 | An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma | terminated | — | 113 | Hoffmann-La RocheINDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT02020941 | Carfilzomib in Treating Patients With Multiple Myeloma in First Relapse or Refractory to First-Line Therapy | terminated | Phase 2 | 10 | Attaya SuvannasankhaOTHER | 1 | Nov 2, 2016 |
| clinicaltrials |
| NCT01541072 | Lymphocyte Reconstitution After Administration of Pegfilgrastim Versus Filgrastim After Peripheral Stem Cell Transplantation(PALM2) | terminated | N/A | 34 | Centre Leon BerardOTHER | 1 | Nov 1, 2016 | clinicaltrials |
| NCT00098371 | Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | terminated | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Oct 24, 2016 | clinicaltrials |
| NCT01186458 | Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma | terminated | Phase 2 | 4 | Hoosier Cancer Research NetworkOTHER | 1 | Oct 24, 2016 | clinicaltrials |
| NCT01517347 | Efficiency Study of Low Dose of IL-2 to Prevent Relapse in Standard Risk Leukemia After Transplantation | terminated | N/A | 90 | Peking University People's HospitalOTHER | 1 | Oct 24, 2016 | clinicaltrials |
| NCT02147873 | Study of Azacitidine With or Without Birinapant in Subjects With MDS or CMMoL | terminated | Phase 2 | 118 | TetraLogic PharmaceuticalsINDUSTRY | 4 | Oct 20, 2016 | clinicaltrials |
| NCT01144403 | A Study of MabThera (Rituximab) Addition to Regularly Prescribed Chemotherapy in Patients With Untreated Mantle Cell Lymphoma. | terminated | Phase 2 | 8 | Hoffmann-La RocheINDUSTRY | 1 | Oct 18, 2016 | clinicaltrials |
| NCT01699581 | Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant | terminated | Phase 2 | 35 | Greg MonohanOTHER | 1 | Oct 18, 2016 | clinicaltrials |
| NCT00788606 | R-CHOP-B Bevacizumab for Diffuse Large B Cell Lymphoma | terminated | Phase 2 | 7 | Royal Marsden NHS Foundation TrustOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT01188915 | Personalised Program for Women Treated for Hodgkin Disease(PROPER) | terminated | N/A | 51 | Institut Paoli-CalmettesOTHER | 1 | Oct 14, 2016 | clinicaltrials |
| NCT00912899 | A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 | 12 | Cougar Biotechnology, Inc.INDUSTRY | 1 | Oct 7, 2016 | clinicaltrials |
| NCT01423760 | Common Safety Follow-up Trial of Tecemotide (L-BLP25) | terminated | N/A | 27 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Oct 6, 2016 | clinicaltrials |
| NCT00278265 | Methotrexate Followed by Fludarabine in Patients With T-Cell Large Granular Lymphocytic Leukemia | terminated | Phase 2 | 12 | German CLL Study GroupOTHER | 1 | Oct 3, 2016 | clinicaltrials |
| NCT02047149 | Evaluating the Safety of Zileuton (Zyflo®) in Combination With Dasatinib (Sprycel®) in Chronic Myelogenous Leukemia | terminated | Phase 1 | 2 | University of Massachusetts, WorcesterOTHER | 1 | Sep 30, 2016 | clinicaltrials |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | terminated | Phase 1 | 155 | Mirna Therapeutics, Inc.INDUSTRY | 2 | Sep 27, 2016 | clinicaltrials |
| NCT00281931 | Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients With Prolymphocytic Leukemia | terminated | Phase 2 | 21 | German CLL Study GroupOTHER | 1 | Sep 26, 2016 | clinicaltrials |
| NCT00416910 | Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | terminated | Phase 3 | 83 | German CLL Study GroupOTHER | 0 | Sep 26, 2016 | clinicaltrials |
| NCT02573935 | Clarithromycin in Multiple Myeloma Induction Therapy(CLAIM) | terminated | Phase 2 | 58 | Henrik GregersenOTHER | 1 | Sep 20, 2016 | clinicaltrials |
| NCT00920153 | Three Different Therapy Regimens in Treating Patients With Previously Untreated Hodgkin Lymphoma | terminated | Phase 3 | 442 | French Innovative Leukemia OrganisationOTHER | 1 | Sep 16, 2016 | clinicaltrials |
| NCT01985477 | Revlimid / All-Trans Retinoic Acid (ATRA) / Dexamethasone in Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 | 2 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2016 | clinicaltrials |
| NCT01121757 | Epigenetic Modulation in Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma | terminated | Phase 2 | 11 | Duke UniversityOTHER | 1 | Sep 12, 2016 | clinicaltrials |
| NCT00984828 | Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients | terminated | Phase 2 / Phase 3 | 23 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Sep 8, 2016 | clinicaltrials |
| NCT02146846 | Population Pharmacokinetics of Imatinib in CML Patients in Iran | terminated | — | 170 | Kerman University of Medical SciencesOTHER | 1 | Sep 7, 2016 | clinicaltrials |
| NCT02808091 | Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma(Gifox-B) | terminated | Phase 2 | 7 | National Cancer Centre, SingaporeOTHER | 1 | Sep 5, 2016 | clinicaltrials |
| NCT00195897 | Early Assessment of Anthracycline-induced Cardiotoxicity (CARDIOTOX) | terminated | — | 6 | Centre Henri BecquerelOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT00771056 | Hydroxychloroquine in Untreated B-CLL Patients | terminated | Phase 2 | 23 | Northwell HealthOTHER | 1 | Aug 22, 2016 | clinicaltrials |
| NCT00814164 | Clofarabine and Daunorubicin in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 2 | 21 | Roswell Park Cancer InstituteOTHER | 1 | Aug 17, 2016 | clinicaltrials |
| NCT00879528 | Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory | terminated | — | 264 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 17, 2016 | clinicaltrials |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT01960387 | Phase II Clofarabine and Cytarabine for Newly Diagnosed Acute Myeloid Leukemia(UPCI 13-066) | terminated | Phase 2 | 2 | University of PittsburghOTHER | 1 | Aug 2, 2016 | clinicaltrials |
| NCT01078974 | Pomalidomide, Dexamethasone and Rituximab in Waldenstrom's Macroglobulinemia | terminated | Phase 1 | 7 | Steven P. Treon, MD, PhDOTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT01096810 | Study of TBL 12 Sea Cucumber Extract for Patients With Untreated Asymptomatic Myeloma | terminated | Phase 2 | 20 | Jagannath, Sundar, M.D.INDIV | 1 | Jul 22, 2016 | clinicaltrials |
| NCT02739594 | Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma(COMPARE) | terminated | Phase 3 | 89 | Hoffmann-La RocheINDUSTRY | 1 | Jul 22, 2016 | clinicaltrials |
| NCT01436084 | SB1518 for Patients With Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT02046928 | Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 5 | Ångstrom PharmaceuticalsINDUSTRY | 1 | Jul 13, 2016 | clinicaltrials |
| NCT00983346 | Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients | terminated | Phase 2 | 17 | University of UtahOTHER | 1 | Jul 11, 2016 | clinicaltrials |
| NCT00004239 | 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment | terminated | Phase 1 | 10 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 4, 2016 | clinicaltrials |
| NCT00004933 | Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa | terminated | Phase 3 | 5 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 4, 2016 | clinicaltrials |
| NCT01144754 | Observational Study of Diffuse Large B Cell Primary Breast Lymphomas Treated With RCHOP +/- XRT | terminated | — | 1 | Stanford UniversityOTHER | 1 | Jul 1, 2016 | clinicaltrials |
| NCT01649791 | Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic Leukemia | terminated | N/A | 8 | Roswell Park Cancer InstituteOTHER | 1 | Jun 30, 2016 | clinicaltrials |
| NCT01108497 | Genome, Proteome and Tissue Microarray in Childhood Acute Leukemia | terminated | — | 235 | Stanford UniversityOTHER | 1 | Jun 24, 2016 | clinicaltrials |
| NCT01556828 | Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing | terminated | — | 70 | Stanford UniversityOTHER | 1 | Jun 24, 2016 | clinicaltrials |
| NCT02273856 | Multicentre Registry of Treatments and Outcomes in Patients With Chronic Lymphocytic Leukaemia (CLL) Or Indolent Non Hodgkin's Lymphoma (iNHL)(NADIR) | terminated | — | 25 | Astellas Pharma International B.V.INDUSTRY | 7 | Jun 21, 2016 | clinicaltrials |
| NCT00185523 | Allogeneic Transplantation for Patients With Acute Leukemia or Chronic Myelogenous Leukemia (CML) | terminated | — | 88 | Stanford UniversityOTHER | 1 | Jun 16, 2016 | clinicaltrials |
| NCT00751296 | Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)(Rev-CLL) | terminated | Phase 2 | 27 | University Health Network, TorontoOTHER | 1 | Jun 16, 2016 | clinicaltrials |
| NCT01536067 | Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia | terminated | Phase 2 | 3 | Roswell Park Cancer InstituteOTHER | 1 | Jun 10, 2016 | clinicaltrials |
| NCT02080416 | Nelfinavir for the Treatment of Gammaherpesvirus-Related Tumors | terminated | Early Phase 1 | 1 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 10, 2016 | clinicaltrials |
| NCT00313053 | Study of mAb 216 With Chemotherapy for Treatment of Pediatric Relapsed or Refractory B-progenitor Acute Lymphoblastic Leukemia | terminated | Phase 1 | 4 | Clare TwistOTHER | 1 | Jun 3, 2016 | clinicaltrials |
| NCT01658904 | Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Nov 2, 2016source: clinicaltrials